LifeMD, Inc. (LFMDP)
| Market Cap | 151.35M -53.7% |
| Revenue (ttm) | 191.59M +19.7% |
| Net Income | -2.91M |
| EPS | -0.09 |
| Shares Out | 48.20M |
| PE Ratio | n/a |
| Forward PE | 86.49 |
| Dividend | $2.22 (9.53%) |
| Ex-Dividend Date | Jul 2, 2026 |
| Volume | 499 |
| Open | n/a |
| Previous Close | 23.28 |
| Day's Range | n/a |
| 52-Week Range | 18.50 - 24.20 |
| Beta | 2.06 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About LFMDP
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men’s telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men’s health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications,... [Read more]
News
UPDATE - LifeMD Reports Second Quarter 2026 Results
UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47.3 million, within the Company's guidance range of $47 million to $50 million; adjusted EBITDA...
LifeMD Earnings Call Transcript: Q2 2026
Q2 revenue was $47.3M, with gross margin expanding to 89% and recurring bill revenue at 84%. Strategic shifts to branded therapies, longer memberships, and diversified acquisition channels led to a revised 2026 outlook, but profitability is expected to improve in H2.
LifeMD Earnings release: Q2 2026
LifeMD released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
LifeMD Slides: Q2 2026
LifeMD has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
LifeMD Quarterly report: Q2 2026
LifeMD has published its Q2 2026 quarterly earnings report on August 5, 2026.
LifeMD to Report Second Quarter 2026 Financial Results on August 5
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and six mont...
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to h...
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing arrangement with LifeMD for the XYOSTED self-pay program, l...
LifeMD Appoints Umesh Sripad as Chief Technology Officer
Seasoned Technology Executive Brings More Than Two Decades of Large-Scale Digital Transformation Experience to Support LifeMD's Next Phase of Growth Seasoned Technology Executive Brings More Than Two ...
LifeMD Transcript: 16th Annual LD Micro Invitational Conference
A leading virtual care provider is expanding from men's health into high-growth areas like GLP-1 weight management, women's health, psychiatry, and cardiology, leveraging proprietary AI and integrated pharmacy infrastructure. Strong revenue growth, high margins, and a shift toward insurance coverage position the business for continued expansion and profitability.
LifeMD to Participate in Upcoming Investor Conferences
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading platform for virtual primary care services, today announced that management will be participating in two upcoming inve...
LifeMD Slides: Investor presentation
LifeMD has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
LifeMD Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue of $50.2M, record subscriber growth, and strong momentum in weight management and women's health. Gross margin expanded to 88%, and full-year guidance was reaffirmed, with profitability expected in the second half as acquisition costs decline.
LifeMD Earnings release: Q1 2026
LifeMD released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
LifeMD Slides: Q1 2026
LifeMD has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
LifeMD Quarterly report: Q1 2026
LifeMD has published its Q1 2026 quarterly earnings report on May 6, 2026.
LifeMD Reports First Quarter 2026 Results
First quarter 2026 revenue of $50.2 million and adjusted EBITDA loss of $4.5 million, above and in line, respectively, with the Company's guidance. Gross margin increased approximately 420 basis point...
LifeMD Proxy statement: Proxy filing
LifeMD filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
LifeMD Proxy statement: Proxy filing
LifeMD filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
LifeMD Proxy statement: Proxy filing
LifeMD filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
LifeMD to Report First Quarter 2026 Financial Results on May 6
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ende...
LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect® LifeMD expands its weight ...
LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD's collaboration with Novo Nordisk Delivering up to $1,200 in annual patient savings on branded GLP-1 therap...
LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Offi...
LifeMD Earnings Call Transcript: Q4 2025
Delivered record Q4 and full-year results with 25% revenue growth, strong subscriber gains, and margin expansion. Aggressive investments in patient acquisition and AI-driven care are expected to drive 2026 revenue to $220–$230 million, with pharmacy and specialty care as key growth drivers.